Arcadia Biosciences, Inc.
Close on Oct 19, 2026
- Market cap
- $433.92K
- P/E (TTM)
- –
- Dividend yield
- –
About Arcadia Biosciences
Crude Petroleum & Natural Gas, SIC 1311
Arcadia Biosciences develops and sells consumer beverage products focused on health and wellness. The company’s core offering is its Zola coconut water line, which provides hydration across several flavors including original, pulp, espresso, and pineapple. Previously focused on agricultural biotechnology, crop traits, and wheat products, the business has divested its historical wheat traits, patent rights, and food brands to concentrate on its beverage operations. Arcadia distributes its beverages primarily to grocery retailers and foodservice distributors across the market.
The company operates out of leased headquarters located in Dallas, Texas. Sourcing, growing, harvesting, and packaging for its coconut water take place at origin in Thailand, with finished goods imported into the United States. As of late 2025, Arcadia employed a core workforce of eight employees across executive management, operations, finance, legal, and administration. It also maintained a portfolio of 24 issued patents and five registered trademarks in the United States.
Summary of the business section of Arcadia Biosciences's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Arcadia Biosciences, Inc.
- Founded
- 2002
- Headquarters
- Dallas, TX
- Address
- 5956 Sherry Lane, Suite 2000
- Phone
- (214) 974-8921
- Website
- arcadiabio.com
- Employees
- 8, Dec 31, 2025
- Industry
- Crude Petroleum & Natural Gas
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Deloitte & Touche LLP, Tempe, AZ, United States
Stock & identifiers
- Ticker
- RKDA
- Exchange
- Nasdaq
- IPO date
- May 15, 2015
- Shares outstanding
- 2M, Aug 6, 2026
- Public float
- $5.74M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-40 reverse, Mar 30, 2023; 1-for-40 reverse, Mar 1, 2023; 1-for-20 reverse, Mar 20, 2018; 1-for-20 reverse, Jan 24, 2018
- SEC CIK
- 1469443
- CUSIP
- 039014303
- ISIN
- US0390143032
- LEI
- 54930027ZPNA80B8O763
- EIN
- 81-0571538
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Thomas J. Schaefer | Chief Executive Officer | 2,819 |
| Mark Kawakami | Chief Financial Officer | 2,681 |
| Lilian Shackelford Murray | Director | 8,524 |
| Kevin Comcowich | Director | 20,000 |
| Gregory D. Waller | Director | – |
| Amy Yoder | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Thomas JSchaefer | $469.00K | $380.17K | $218.43K | $36 | – |
| FY2024 Stanley EJacot | $518.11K | $532.04K | $262.50K | $-7 | – |
| FY2024 Thomas JSchaefer | $499.48K | $567.35K | $262.50K | $-7 | – |
| FY2023 Stanley EJacot | $525.18K | $487.53K | $363.40K | $8 | – |
| FY2022 Kevin Comcowich | $208.09K | $145.95K | $430.71K | $30 | – |
| FY2022 Stanley EJacot | $749.47K | $565.21K | $430.71K | $30 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight employees, including management, operations, accounting/finance, legal and administration personnel.”
Corporate history
Events identified from SEC filings